PharmTech Drug Digest 11.20
News|Articles|January 29, 2015

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-02-04-2015
  • Volume 11
  • Issue 2

PPD Announces Completion of Clinical Studies Facility in Ireland

PPD announced that it completed an expansion to its Athlone, Ireland facility, resulting in 20,000-square-feet of dedicated space for warehousing and distribution purposes.

 

Pharmaceutical Product Development (PPD) announced on Jan. 28, 2015 that it completed an expansion to its clinical supply facility in Athlone, Ireland. The updated facility will now feature 20,000-square-feet of space dedicated to storing, packaging, and labeling for clinical trials conducted for clients. The expansion will allow PPD to double its packaging warehousing capabilities and quadruple its distribution services. The facility will also be able to provide syringes, IV pumps, other machinery, and dedicated project managers, who will serve as a single point of contact for clients. In Athalone, PPD operates a nearly 50,000-square-foot facility, with approximately 18,000-square-feet in good manufacturing practices laboratory space.

“The expansion of our clinical supplies facility in Athlone represents an important investment in the continued growth of our global operations. Our ability to expand our support of clinical trials enables us to meet our clients’ growing demand for these services in Europe, the Middle East, and Africa. This strategic location makes it operationally and financially efficient to ship supplies to any of those countries, often directly to investigative sites-which can result in faster turnaround at lower cost for our clients, and more efficient and effective operations for PPD,” said Susan Atkinson, PhD, senior vice-president of global biometrics at PPD, in a press release.

Source: PPD


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.